Kepler Capital Remains a Buy on Bayer (0P6S)
Kepler Capital analyst Christian Faitz maintained a Buy rating on Bayer on January 26 and set a price target of €53.00. The company’s shares closed last Monday at €46.37.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Faitz covers the Basic Materials sector, focusing on stocks such as BASF SE, Wacker Chemie AG, and K+S Aktiengesellschaft. According to TipRanks, Faitz has an average return of 6.9% and a 50.91% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bayer with a €38.46 average price target, implying a -17.05% downside from current levels. In a report released on January 23, J.P. Morgan also maintained a Buy rating on the stock with a €50.00 price target.
Based on Bayer’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of €9.66 billion and a GAAP net loss of €963 million. In comparison, last year the company earned a revenue of €9.97 billion and had a GAAP net loss of €4.18 billion
Read More on GB:0P6S:
Disclaimer & DisclosureReport an Issue
- Bayer investing over C$45M to build canola research, development facility
- Bayer, Vanderbilt University Medical Center enter five-year collaboration
- Bayer ‘welcomes’ Supreme Court review of Durnell litigation
- U.S. Supreme Court to hear Bayer’s appeal of Roundup lawsuits, Bloomberg says
- Bayer to acquire AT-01 and AT-05 from Attralus, terms undisclosed
